NCT04678453View on ClinicalTrials.gov

Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD)

PHASE1TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 6, 2021

Primary Completion Date

August 16, 2023

Study Completion Date

January 31, 2024

Conditions
Alzheimer DiseaseNeuro-Degenerative Disease
Interventions
BIOLOGICAL

SNK01

Patient-specific ex vivo expanded autologous natural killer cells

Trial Locations (1)

22010

Hospital Angeles Tijuana, Tijuana

Sponsors
All Listed Sponsors
lead

NKGen Biotech, Inc.

INDUSTRY

NCT04678453 - Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD) | Biotech Hunter | Biotech Hunter